Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
130 Cards in this Set
- Front
- Back
|
Decscribe Female Menstral Cycle |
GnRH, LH, FSH, Estrogen, Progestin, |
|
|
Estrace, Climara, Vivelle |
Estradiol (Estrogen Receptor Agonists) |
|
|
Ogen |
Estrone/Estropiprate (Estrogen Receptor Agonists) |
|
|
Premarin |
Conjugated Estrogen (Estrogen Receptor Agonists) |
|
|
Menest |
Esterified Estrogens (Estrogen Receptor Agonists) |
|
|
Cenestin, Enjuvia |
Synthetic Conjugated Estrogens (Estrogen Receptor Agonists) |
|
|
Estrogen (Vaginal Tabs) |
Vagifem) (Estrogen Receptor Agonists) |
|
|
Estrogen (Vaginal Ring) |
Estring, Femring (Estrogen Receptor Agonists) |
|
|
Uses of Estrogens |
Tx of hot flashes (immediately after menopause), topical tx of vaginal atropy |
|
|
ADRS of estrogens (6 Major) |
1.) Increased growth of estrogen dependant tissue (Uterine and Breast)
2.) Lowered total cholesterol, lowered LDL raised HDL 3.) Increased synthesis of clotting factors (risk of MIs, CVAs, DVTs, PEs w/ tx) 4.) Edema and sodium retention 5.) Psych: HA, Depression 6.) Do not use in preganancy |
|
|
Raloxifiene |
Evista (SERM) ER agonist at bone No effect on uterine tissue Antagonist in breast and blood vessel ERs Tx: Osteoporsis |
|
|
Tamoxifene |
Volvadex (SERM) ER Agonist at bone and endometrium (in creased bone and endometrial growth) Antagonist at breast and blood vessel ERs Tx: Breast cancer |
|
|
Toremifene |
SERM (Not tamoxifene!) ER Agonist at bone and endometrial tissue Antagonist at breast and blood vessels Tx: Breast cancer |
|
|
Ospemifene |
Osphena, SERM ER agonist at vaginal tissue, increases growth of uterine/vaginal tissue (risk of cancer/bleeding) and hotflashes. ER antagonist at breast Tx: Vaginal atrophy |
|
|
Duavee |
Bazedoxfine + conjugated estrogens Bazedoxifine (ER agonist) decreases risk of breast cancer + osteoporosis Conjugated Estrogens = agonists at bone, vaginal blood vessels |
|
|
FLuvestrant |
Falsodex (SERD) MOA: binds alpha isoform of estrogen receptor = marks it for degredation by proteases Tx: Breast Cancer (estrogen dependant) |
|
|
Monophasic BC |
Combo Estrogen/Progesterone SAME dose of both WHOLE TIME 99.9% efficacy, up to 2 days can be missed w/o reduction in efficacy |
|
|
Biphasic BC |
Combo Estrogen/Progesterone Same dose estrogen, 1st half low dose progesterone, second half high dose 99.9% efficacy, up to 2 days can be missed w/o reduction in efficacy |
|
|
Triphasic BC |
Combo Estrogen/Progesterone Same dose estrogen, 1/3 low progesterone, 2/3 med progesterone, 3/3 high progesterone 99.9% efficacy, up to 2 days can be missed w/o reduction in efficacy |
|
|
Mini-Pill BC |
ONLY Progestin 99% efficacy, 60% fx from FSH/LH reduction, rest from thickening of cervical mucus 1 missed dose = reduced efficacy |
|
|
Clomiphene |
Clomid Estrogen Receptor Antagonist (Central) Tx of F and M infertility, increases FSH = increased follicle growth and spermatogenesis (requires functional release of FSH and LH) ADRs: Opposite of estrogen |
|
|
rDNA FSH, LH and HcG |
Exogenous Gonadotropins Tx: Inferfility FSH x10d for follicle growth LH or HcG for rupture/ovulation ADRS: OHSS, multiple births |
|
|
Ganorelix |
GNRH Receptor Antagonist Tx: Inferfility Decreases LH release = decreased folicle rupture used in combo w/ exogenous FSH (for growth) |
|
|
Citrorelix |
GNRH Receptor Antagonist Tx: Inferfility Decreases LH release = decreased folicle rupture used in combo w/ exogenous FSH (for growth) |
|
|
Menotropins |
FSH+ LH Tx: Male Infertility Direct action, stimulates spermatogensis |
|
|
Gonadorelin |
Synthetic GnRH Diagnostic tool for Male infertility Admin= Release of LH+ FSH = use clomid Admin= NO release of LH or FSH = use menotropins |
|
|
Testosterone |
Depotestosterone Exogenous T For Low T ADRs: Increased LIPIDS, BPH/Prostate cancer |
|
|
Testosterone |
Androderm Patch, Androgel, Testim (Foam) Exogenous T For Low T ADRs: Increased LIPIDS, BPH/Prostate cancer |
|
|
Methytestosterone |
Orally Available T Exogenous T For Low T ADRs: Increased LIPIDS, BPH/Prostate cancer |
|
|
Estratet/Syntest |
Orally avalable Estrogen w/ Testosterone (some) Hormone replacement |
|
|
Fluoxymestrone |
Halotestin Anabolic Steroid Increased Lipids, Prostate fx, hepatotoxic, gynemacastia, infertility |
|
|
Oxandrolone |
Anabolic Steroid Increased Lipids, Prostate fx, hepatotoxic, gynemacastia, infertility |
|
|
Oxymetholone |
Anabolic Steroid Increased Lipids, Prostate fx, hepatotoxic, gynemacastia, infertility |
|
|
Nandrolone |
Deca-Durabolin Anabolic Steroid Increased Lipids, Prostate fx, hepatotoxic, gynemacastia, infertility |
|
|
Stanozolol |
Winstrol Anabolic Steroid Increased Lipids, Prostate fx, hepatotoxic, gynemacastia, infertility |
|
|
Danocrine |
Central Androgen Receptor Agonist (decreases FSH and LH release) Tx: Endometriosis ADRs: Adrogenic fx, increased lipids, intracranial HTN, Clotting PREG Category: X |
|
|
Abarelix |
GnRH Receptor Antagonist Tx of prostate cancer IMMUNORESPONSE REQUIRES OBSERVATION |
|
|
Degarelix |
GnRH Receptor Antagonist Tx of Prostate cancer |
|
|
Leupolide |
Lupron GnRH Receptor AGONIST Tx of prostate cancer |
|
|
Nafarelin |
GnRH Receptor AGONIST Tx of prostate Cancer |
|
|
Goserlelin |
GnRH Receptor Agonist Tx of Prostate cancer |
|
|
Buserelin |
GnRH Receptor Agonist Tx of Prostate Cancer |
|
|
Histrelin |
GnRH Receptor Agonist Tx of Prostate Cancer |
|
|
Triptorelin |
GnRH Receptor Agonist Tx of Prostate Cancer |
|
|
Finaseride (2) |
Propecia: tx of Allopecia Proscar: Tx of BPH 5 alpha reducase II inhibitor (hair and prostate) ADR: decreased libido |
|
|
Dutasteride |
Avodart 5 alpha reductase I and II inhbitor Tx of BPH ADR: decreased libido |
|
|
Flutamide |
Eulexin Androgen receptor antagonist Tx of prostate cancer HEPATOTOXIC |
|
|
Bicalutamide |
Casodex Androgen receptor antagonist Tx of prostate cancer |
|
|
Nilutamide |
Nilandron Androgen receptor antagonist Tx of prostate cancer |
|
|
Somatropin |
Human rDNA GH (Identical AAs) Tx: Relplacement + idopathic short stature ADRs: Intracranial HTN, Visual changers, risk of cancer ILLEGAL TO USE OFF LABEL |
|
|
Somatrem |
Altered Human rDNA GH Tx: Relacement + idopathic short stature ADRs: Intracranial HTN, visual changes, risk of cancer ILLEGAL TO USE OFF LABEL |
|
|
Sermorelin and Tesamorelin |
GHRH Analogues/mimics Dx of pituitary deficiencies Tx of Low GH (maintains GH feedback) ADRs: Intracranial HTN, visual changes, increased growth of cancer |
|
|
rDNA Human IGF-1 |
IGF-1 Underproducers
Abuse potential |
|
|
Octreotide |
Sandostatin MOA: SST-5 Agonist Tx: gigantism, acromegdaly (off label hypoglycemia) ADRs: GIT Fx, GALLSTONES (decreased fat absorp), suppression of Insulin release |
|
|
Lanreotide |
SST-5 Agonist
Tx: Gigantism Acromegdaly (off label hypoglycemia) ADRs: GIT Fx, Gallstones, decreased Fat absorption, suppression of insulin release |
|
|
Pasireotide |
Signifor MOA: SST-5 Agonist Tx: gigantism, acromegdaly (off label hypoglycemia) ADRs: GIT Fx, GALLSTONES (decreased fat absorp), suppression of Insulin release |
|
|
Bromocriptine (hehe) |
D2 Receptor Agonist (At pituitary)
Tx: Acromedgadly (Alt), hyperprolactemia, parkinsons ADRs: GIT Fx, psychosis, HA, asthenia, |
|
|
Pegvisomant |
Somavert MOA: GH receptor Agonist (peptide) Tx: 2nd line tx of acromegdaly ADRs: Ab development (DURATION DEPENDANT) limit use! |
|
|
Afrezza |
Human insulin, ultra rapid (inhaled) |
|
|
Humalog |
Insulin Lispro
Rapid Acting Insulin |
|
|
Novolog |
Insulin Aspart Rapid Acting Insulin |
|
|
Apidra |
Insulin Glulisine
Rapid Acting Insulin |
|
|
Humulin R, Novolin R |
Regular Insulin Intermediate acting |
|
|
Humulin N, Novolin N |
Insulin NPH Intermediate Acting |
|
|
Lantus, Toujeo |
Insulin Glargine Long Acting |
|
|
Levemir |
Insulin Detemir Long acting |
|
|
Chlorpropamide |
1st gen sulfonylurea |
|
|
Micronase |
Glyburide 2nd gen sulfonylurea (Secretagogue) ACTIVE METABOLITE |
|
|
Glucotrol |
Glipizide 2nd gen sulfonylurea (Secretagogue) INACTIVE METABOLITE |
|
|
Amaryl |
Glimpiride
2nd gen sulfonylurea (Secretagogue) |
|
|
Prandin |
Repaglinide
Meglitinide (secretagogue) LESS EFFECTIVE THAN Sulfonylureas |
|
|
Starlix |
Nateglinide Meglitinide (secretagogue) Less effective than sulfonylureas |
|
|
Byetta |
Exenatide GLP-1 Receptor Agonist, Secretagogue ADRs: N/V pancreatitis Teratogenic |
|
|
Liraglutide |
Victoza GLP-1 Receptor agonist (Secretagogue ADRs: N/V pancreatitis, teratogenic |
|
|
Tanzeum |
Albiglutide GLP-1 Receptor Agonist (Secretaguge) ADRs: N/V pancreatitis Teratogenic |
|
|
Januvia |
Sitagliptin DPP-IV Inhibitor (Secretagogue) PO Less efficacious than GLP-1 agonists |
|
|
Onglyza |
Savagliptin DPP-IV Inhibitor (Secretagogue) PO Less efficacious than GLP1 agonists |
|
|
Tradjenta |
Linagliptin DPP-IV Inhibitor (Secretagogue) PO Less efficacious than GLP-1 analogues |
|
|
Symlin |
Pramlintide Amylin Analogue (secretagogue) SLows gastric emptying and decreases glucagon secretion from pancreas INSULIN DOSE MUST BE LOWERED!!! |
|
|
Glucophage |
Metformin Biguanide MOA: Activates AMPK = increased ox of FA, hepatic insulin sensitivty, decreased gluconeogensis and glycogenolysis MUST be D/C b4 contrast dye due to risk of ARF => build up and lactic acidosis |
|
|
Actos |
Pioglitazone Thiazolidinedione PPARg agonists = decreased lipolysis decreased leptin, tnfa and adiponectin = increased insulin sensitivity CONTRA: HF IV ADRs: Edema weight gain, MI possible, hepatotox |
|
|
Avandia |
Rosiglitazone Thiazolidinedione PPARg agonists = increased lipolysis decreased leptin, tnfa, and adiponectin = increased insulin sensitivity CONTRA: HF IV ADRs: Edema, weight gain, MI possible, hepatotox |
|
|
Precose |
Arcarbose Alpha-glucosidase inhibitor |
|
|
Gyset |
Miglitol Alpha-glucosidase inhibitor |
|
|
Farxiga |
Dapagliflozin SGL2-Inhibitor |
|
|
Invokana |
Canaglifloxin SGLT2-Inhibitor |
|
|
Empagliflozin
|
SGLT2-Inhibitor |
|
|
Alendronate |
Fosamax Bisphosphate |
|
|
Risendronate |
Actonel Bisphosphate |
|
|
Ibandronate |
Boniva Bisphosphate |
|
|
Pamindronate |
Aredia Bisphosphate |
|
|
Zolendronate |
Reclast Bisphosphate |
|
|
Denosumab |
Prolia Mab Directed at RANK L (ligand) prevents maturation of Osteoclasts |
|
|
Calcitonin (IN) |
IN spray inhibits osteoclast activity |
|
|
Teriparatide |
Forteo (a PTH fragment w/ different folding) Adrogenic stimulator of Osteoclasts, increases bone mineral density DO NOT USE FOR MORE THAN 2 YEARS risk of osteosarcoma |
|
|
Sensipar |
Allosteric modulator of CSR on parathyroid, increases Ca sensitivity Tx of hyperparathyroidism |
|
|
Natpara |
Exogenous PTH Tx: Hypoparathyroidism often seen in Endstage renal disease |
|
|
Levothyroxine, levoxyl, levothyroid |
T4 Supplement
|
|
|
Synthroid |
T4 Supplement |
|
|
Unithroid |
T4 SUpplement
|
|
|
Liothyronine |
Cytomel T3 supplement |
|
|
T3 + T4 |
Litrix (Thyrolar) |
|
|
Dessicated Thyroid |
Armour thyroid |
|
|
PTU |
Propylthiouracil Thioperoxidase Inhibitor (inhibits iodination of Tyr residues and coupling of DIT/MIT) Tx of hyper parathyroidism |
|
|
Methimoxazole |
Thioperoxidase inhibitor Inhibits iodination of Tyr residues and coupling of DIT/MIT Tx of hyper parathyroidism |
|
|
High dose Iodine supplement |
Tx of radiation exposure Inhibits Na/I symport and release of T3/T4 from thyroid |
|
|
SSKI and Lugol Soln |
Potassium Iodide, Use as mucus expectorant in Cystic fibrosis |
|
|
I 131 |
Radioactive Iodine Tx of hyperthyroidism Capsuled taken, radioactive I absorpbed and taken up by kidney where it releases beta particles and kills off thyroid |
|
|
Omalizumab |
Xolair Mab directed against IgE, prevents mast cell SENSITIZATION Tx of hypersensitivty RXNs (not 1st line) |
|
|
Cromolyn |
Mast cell stabilizer Prevents degranulization of mast cells (not cross linking) Tx of hypersensitivity |
|
|
Nedocromil |
Mast cell stabilizerPrevents degranulization of mast cells (not cross linking)Tx of hypersensitivity |
|
|
Montelukast, pranlukast, zafirlukast |
Singulair, no brand, accolate CysLT1 receptor antagonist Tx of hypersensitivty |
|
|
Zileutin CR |
Zyflo CR 5-LIpoxygenase inhibitor, prevents AA conversion to Leukotrienes Tx of hypersenstivity |
|
|
Epi-Pen |
Epinephrine Alpha1 ag = vasoconstrict Beta 2 ag = bronchodilation Tx of anaphylaxis |
|
|
Diphenhydramine |
Benadryl 1st gen antihistamine |
|
|
Clemastine |
Tavist 1st gen antihistamine |
|
|
Chlorpheniramine |
Chlor-Trimenton 1st gen antihistamine |
|
|
Brompheniramine |
in bromfed 1st gen antihistamine |
|
|
Meclizine |
Antivert 1st gent antihistamine tx motion sickness |
|
|
Cylcizine |
1st gen antihistamine Tx motion sickness |
|
|
Hydroxyzine |
Atarax/Vistaril 1st gen antihistamine |
|
|
Dimehydramine |
Dramamine 1st gen antihistamin Tx: motion sickness |
|
|
Promethazine |
Phenergan D2 receptor antagonist w/ H1 competitive antag properties |
|
|
Cyproheptadine |
Periactin 5-HT2 receptor antagonist + H1 competitive antag |
|
|
Doxepine |
TCA w/ H1 competitve antag properties |
|
|
Loratadine |
Claritin 2nd gen anti-histamine |
|
|
Ceterizine |
Zyrtec 2nd gen antihistamine |
|
|
Azelastin |
Astelin
2nd gen antihistamine |
|
|
Desloratadine |
Clarinex 2nd gen antihistamine |
|
|
Fexofenadine |
Allegra 2nd gen antihistamine |
